Blue Trust Inc. Grows Holdings in DexCom, Inc. (NASDAQ:DXCM)

Blue Trust Inc. raised its position in DexCom, Inc. (NASDAQ:DXCM) by 101.9% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,779 shares of the medical device company’s stock after buying an additional 898 shares during the period. Blue Trust Inc.’s holdings in DexCom were worth $119,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of DXCM. Team Hewins LLC increased its stake in shares of DexCom by 3.4% in the first quarter. Team Hewins LLC now owns 2,555 shares of the medical device company’s stock worth $354,000 after buying an additional 83 shares during the last quarter. Bleakley Financial Group LLC raised its stake in shares of DexCom by 1.3% in the 1st quarter. Bleakley Financial Group LLC now owns 6,856 shares of the medical device company’s stock valued at $951,000 after purchasing an additional 87 shares in the last quarter. Capital Insight Partners LLC lifted its position in shares of DexCom by 2.5% during the second quarter. Capital Insight Partners LLC now owns 3,690 shares of the medical device company’s stock worth $418,000 after purchasing an additional 90 shares during the last quarter. HM Payson & Co. grew its stake in DexCom by 6.0% in the first quarter. HM Payson & Co. now owns 1,780 shares of the medical device company’s stock worth $247,000 after purchasing an additional 100 shares in the last quarter. Finally, State of Alaska Department of Revenue increased its holdings in DexCom by 0.3% in the first quarter. State of Alaska Department of Revenue now owns 41,830 shares of the medical device company’s stock valued at $5,801,000 after buying an additional 105 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at DexCom

In other DexCom news, EVP Sadie Stern sold 426 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the sale, the executive vice president now directly owns 75,451 shares in the company, valued at $5,217,436.65. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other DexCom news, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the sale, the executive vice president now directly owns 75,451 shares in the company, valued at approximately $5,217,436.65. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,824 shares of company stock worth $126,390 over the last quarter. 0.30% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on DXCM shares. BTIG Research decreased their target price on DexCom from $156.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, July 26th. Morgan Stanley lowered their target price on shares of DexCom from $120.00 to $75.00 and set an “equal weight” rating for the company in a research note on Friday, July 26th. JPMorgan Chase & Co. raised their price target on shares of DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a research report on Friday. Raymond James lowered their price objective on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research report on Friday. Finally, Leerink Partners cut their target price on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a report on Friday. Six equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $104.59.

DexCom Stock Down 1.8 %

DexCom stock opened at $72.10 on Tuesday. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The stock has a market cap of $28.67 billion, a price-to-earnings ratio of 46.52, a PEG ratio of 2.26 and a beta of 1.18. The company’s 50-day moving average price is $70.00 and its two-hundred day moving average price is $97.18. The company has a current ratio of 2.82, a quick ratio of 2.48 and a debt-to-equity ratio of 1.00.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.